Estimated treatment effects at weeks 12, 24 and 36 in primary outcome
| Estimate of difference between SCT and Control | SE | 95% CI | p Value | |
| Intention-to-treat analysis | ||||
| 6MWT | ||||
| Week 12 | 22.70 | 19.00 | (−15.14 to 60.50) | 0.23 |
| Week 24 | 11.80 | 20.40 | (−28.77 to 52.36) | 0.56 |
| Week 36 | 27.42 | 20.35 | (−13.06 to 67.90) | 0.18 |
| TUG | ||||
| Week 12 | 0.069 | 0.236 | (−0.402 to 0.541) | 0.77 |
| Week 24 | −0.132 | 0.250 | (−0.630 to 0.365) | 0.60 |
| Week 36 | −0.457 | 0.252 | (−0.960 to 0.045) | 0.08 |
| MSWS-12 | ||||
| Week 12 | −4.91 | 4.47 | (−13.82 to 4.00) | 0.28 |
| Week 24 | −0.59 | 4.69 | (−9.91 to 8.73) | 0.90 |
| Week 36 | 0.38 | 4.57 | (−8.71 to 9.47) | 0.93 |
| Secondary analysis | ||||
| 6MWT | ||||
| Week 12 | 39.00 | 18.44 | (2.26 to 75.73) | 0.04 |
| Week 24 | 27.44 | 19.23 | (−10.82 to 65.70) | 0.16 |
| Week 36 | 40.03 | 18.97 | (2.27 to 77.79) | 0.04 |
| TUG | ||||
| Week 12 | 0.204 | 0.255 | (−0.306 to 0.713) | 0.43 |
| Week 24 | −0.020 | 0.261 | (−0.542 to 0.502) | 0.94 |
| Week 36 | −0.367 | 0.262 | (−0.890 to 0.156) | 0.17 |
| MSWS-12 | ||||
| Week 12 | −7.63 | 4.65 | (−16.89 to 1.63) | 0.11 |
| Week 24 | −2.50 | 4.78 | (−12.01 to 7.02) | 0.60 |
| Week 36 | −1.57 | 4.69 | (−10.93 to 7.78) | 0.74 |
MSWS-12, Multiple Sclerosis Walking Scale-12; 6MWT, Six-Minute Walk Test; TUG, Timed Up and Go.